Tom3 schreef op 28 maart 2021 15:03:
www.ncbi.nlm.nih.gov/pmc/articles/PMC..."Importantly, tumor shrinkage was also observed in 3 out of 7 patients refractory to their most recent treatment with brentuximab vedotin, and only 1 out of 7 patients had PD. Like AFM13, brentuximab vedotin targets CD30; however, the effector mechanism of these substances is entirely different: AFM13 activates the patient’s cell-based immune system to target the tumor, whereas brentuximab vedotin delivers a chemotherapeutic agent into the lymphoma cell. Chemotherapies usually result in rapid clinical effects; however, the safety profile is often less favorable, and resistance to the cytotoxic components occurs frequently in relapsed or refractory settings. These characteristics have also been observed with brentuximab vedotin: the ORR for brentuximab vedotin was 50% in a phase 1 study in relapsed or refractory HL30 and 75% in the registration phase 2 study.15 On the other hand, the duration of the effect was short with an overall progression-free survival of <6 months, and the safety was less favorable, with peripheral neuropathy occurring in 42% of the patients in the phase 2 study.15 In contrast to that, clinical response to immunotherapies may occur late, but it may be of longer duration."